NEW YORK (GenomeWeb News) – Genetic Technologies said on Thursday that receipts from customers for its first quarter of Fiscal Year 2014 dropped 17 percent.

For the three months ended Sept. 30, receipts totaled A$1.0 million (US$945,000) down from $A1.2 million, a year ago. The downtick occurred despite a record number of test samples for its flagship non-familial breast cancer risk assessment test called BrevaGen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.